Chardan Capital Markets will host a Leadership Call with HighTide Therapeutics. The call will be moderated by Michael Morabito, PhD, Senior Research Analyst.
May 19, 2020
Learn More
HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes. HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk fac
May 07, 2020
Learn More
Approvals Support Clinical Trials in China and Canada for HTD1801 in Primary Sclerosing Cholangitis
November 19, 2019
Learn More
SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...
October 10, 2019
Learn More
HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.
October 10, 2019
Learn More
Based on Safety Data Review, DMC Recommends Continuing Trial
September 02, 2019
Learn More
© 2023 HighTide Therapeutics, Inc.